Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Cantor Fitzgerald
Daiichi Sankyo
QuintilesIMS
McKesson
McKinsey
Express Scripts
Cerilliant
US Department of Justice
Covington

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 090571

« Back to Dashboard

NDA 090571 describes HEPARIN SODIUM, which is a drug marketed by Abraxis Pharm, Akorn, Chamberlin Parenterl, Dell Labs, Fresenius Kabi Usa, Gland Pharma Ltd, Hospira, Hospira Inc, Lilly, Luitpold, Organon Usa Inc, Parke Davis, Pfizer, Pharm Spec, Pharmacia And Upjohn, Sagent Pharms, Sandoz, Shenzhen Techdow, Smith And Nephew, Solopak, Watson Labs, Watson Labs Inc, West-ward Pharms Int, Baxter Hlthcare, Mcgaw, B Braun, and Pharma Serve Ny, and is included in fifty-eight NDAs. It is available from twelve suppliers. Additional details are available on the HEPARIN SODIUM profile page.

The generic ingredient in HEPARIN SODIUM is heparin sodium. There are seventy-seven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the heparin sodium profile page.
Summary for 090571
Tradename:HEPARIN SODIUM
Applicant:Hospira Inc
Ingredient:heparin sodium
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 090571
Ingredient-typeHeparin
Suppliers and Packaging for NDA: 090571
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 090571 ANDA Hospira, Inc. 0409-2720 0409-2720-03 25 VIAL, MULTI-DOSE in 1 TRAY (0409-2720-03) > 30 mL in 1 VIAL, MULTI-DOSE (0409-2720-32)
HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 090571 ANDA Hospira, Inc. 0409-2720 0409-2720-02 25 VIAL, MULTI-DOSE in 1 TRAY (0409-2720-02) > 10 mL in 1 VIAL, MULTI-DOSE (0409-2720-31)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength1,000 UNITS/ML
Approval Date:Aug 31, 2009TE:APRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength5,000 UNITS/ML
Approval Date:Aug 31, 2009TE:APRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength10,000 UNITS/ML
Approval Date:Aug 31, 2009TE:APRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
McKinsey
Covington
AstraZeneca
Harvard Business School
Julphar
Chinese Patent Office
Cerilliant
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot